David Ellison will continue to serve as Chairman and Chief Executive Officer

Founder and President of Emerson Collective Laurene Powell Jobs and Activision founder Bobby Kotick join as Independent Directors, along with Skydance Co-CEO Ynon Kreiz; former UK Prime Minister Tony Blair to serve as Board Advisor

LOS ANGELES and NEW YORK, Oct. 6, 2026 /PRNewswire/ — Skydance Corporation (NYSE: SKYD) (“Skydance”) today announced the director and advisor designees for the newly combined company, formed through Paramount’s merger with Warner Bros. Discovery, Inc. (NASDAQ: WBD). The designees will join the Skydance Board of Directors, effective immediately.

David Ellison will chair the Board and continue to serve as Skydance’s Chairman and Chief Executive Officer. The Board will include all current members of Paramount’s Board, along with three new additions: Ynon Kreiz, Co-Chief Executive Officer of Skydance, Laurene Powell Jobs, founder and president of Emerson Collective; and Bobby Kotick, founder and former Chief Executive Officer of Activision. Powell Jobs and Kotick will join as Independent Directors.

Powell Jobs is a visionary entrepreneur and one of the most influential leaders in business and philanthropy. She is also a committed investor in journalism and media, supporting quality, independent reporting and storytelling at both the national and local levels. She built her career on creating institutions that endure and drive meaningful change. Her leadership extends across education, climate and community-driven initiatives. As founder and president of Emerson Collective, she pioneered a groundbreaking model that unites venture investing and philanthropic grant-making to tackle society’s most complex challenges, and she has shown a rare gift for identifying bold ideas early and scaling them into lasting impact. That dedication, together with her extensive experience in investing and philanthropy, makes her a valuable addition to Skydance’s board.

Bobby Kotick brings more than three decades of public-company leadership, having served as CEO of Activision for 32 years and built it into one of the world’s most successful video game companies. He paired bold strategic moves, including the company’s merger with Vivendi Games, with disciplined capital allocation and a consistent record of rewarding shareholders. That record culminated in the sale of Activision Blizzard to Microsoft for $68.7 billion, the largest transaction in the history of the video game industry. Throughout his tenure, he showed a rare ability to anticipate shifts in how consumers engage with entertainment, investing in new platforms, new business models and new ways of reaching fans while keeping creative excellence at the center of the enterprise. His experience scaling a franchise-driven business, managing the complexity of a global public company and steering major industry transitions will serve Skydance well as it navigates an evolving media and entertainment landscape.

Former UK Prime Minister Tony Blair will join as a Board Advisor. Blair, who will be acting in a personal capacity, is Executive Chairman of the Tony Blair Institute for Global Change, a not-for-profit organization, which helps leaders govern in the age of AI. His global leadership experience and commitment to innovation position him as an invaluable advisor in shaping Skydance’s strategic priorities.  

Skydance is a creative-first, audience-focused, tech-forward and globally scaled company, and these directors reflect that ambition. Their combined experience across media and entertainment, technology, finance and global affairs will provide strategic guidance and oversight as Skydance brings together its complementary businesses, storytelling capabilities and technology platforms, helping to align our goals and accelerate growth.

Said David Ellison, Chairman and CEO of Paramount, a Skydance Corporation:

“I am delighted to welcome Laurene and Bobby to our Board and honored to have Tony join us as an Advisor. Laurene is a true visionary and one of the great institution builders of our time. Her vision, judgment and unwavering commitment to high-quality journalism and media investments make her a truly exceptional addition to our Board. Through Emerson Collective, she pioneered an innovative model that brings together venture investing and philanthropy to tackle society’s most complex challenges, and she has an extraordinary gift for recognizing bold ideas early and turning them into lasting impact.”

Ellison continued: “Bobby led a global entertainment company through three decades of sustained growth, and he brings real perspective on building enduring franchises and connecting with fans. His record of pairing bold strategic moves with disciplined capital allocation is exactly the experience we need as we bring our businesses together. Tony has led at the highest levels of government, respected for his intellect, strategic vision and ability to bring people together around bold, forward-looking ideas. His global perspective and insight will be invaluable as we turn ambition into results.”

Ellison added: “Together with our other directors, they bring the experience and fresh perspectives we need to build Skydance into an extraordinary company, one that honors the legacies of Paramount and Warner Bros. Discovery while setting a bold course for the future. United by a commitment to creative excellence, innovation and long-term shareholder value, this Board will help us empower our teams, strengthen our businesses and deliver exceptional entertainment to audiences around the world.”

The Director-designees are as follows:

David Ellison, Chairman and Chief Executive Officer of SkydanceBarbara Byrne, Former Vice Chairman of Barclays PLC (Independent Director)Andy Campion, Chairman and CEO of Unrivaled Sports (Independent Director)Gerry Cardinale, Founder, Managing Partner, and Chief Investment Officer, RedBird Capital PartnersSafra A. Catz, Executive Vice Chair and Former CEO, Oracle CorporationAndy Gordon, President of SkydanceJustin G. Hamill, Managing Director and Chief Legal Officer, Silver Lake (Independent Director)Lauren Powell Jobs, Founder and President, Emerson Collective (Independent Director)Bobby Kotick, Founder and former CEO of Activision (Independent Director)Ynon Kreiz, Co-Chief Executive Officer of SkydanceSherry Lansing, Former Chairman and CEO of Paramount Pictures (Independent Director)Paul Marinelli, President, Lawrence Investments, LLCJohn L. Thornton, Chairman of RedBird Capital Partners

About Skydance

Skydance is a next-generation global media and entertainment company, composed of three business segments: Studios, Direct-to-Consumer, and TV Media. Skydance’s portfolio unites legendary brands, including Paramount, Warner Bros., HBO, Paramount+, Pluto TV, CBS, CNN, CBS Sports, TNT Sports, Nickelodeon, Cartoon Network, MTV, Food Network, BET, HGTV, and Comedy Central.

PSKY-IR

View original content:https://www.prnewswire.com/news-releases/skydance-announces-board-adding-ynon-kreiz-laurene-powell-jobs-and-bobby-kotick-as-directors-and-tony-blair-as-advisor-302900350.html

SOURCE Skydance Corporation

Patent-pending methodology combines geospatial, hydrologic and ecological modeling to streamline early-stage project screening

BELLAIRE, Texas, Oct. 6, 2026 /PRNewswire/ — RES (Resource Environmental Solutions, LLC), the nation’s largest dedicated provider of nature-based solutions, today announced the launch of EcoSite IQ, a proprietary methodology developed to help clients identify, evaluate and prioritize environmental projects.

RES delivers nature-based solutions at scale, including ecological restoration, environmental mitigation, water quality improvements and coastal resiliency. By uniting ecological science, engineering, and long-term land stewardship, RES helps public- and private-sector partners address complex regulatory requirements and achieve voluntary ecological objectives.

RES evaluates opportunities early, helping clients understand the environmental and technical conditions that shape a project and developing solutions aligned with their goals. RES specialists guide projects from early feasibility analysis and restoration planning through construction and long-term stewardship. RES also provides consulting services for ecosystem portfolios, helping clients compare opportunities across properties, watersheds or broader geographies and prioritizing investments based on potential environmental benefits, feasibility and project objectives.

EcoSite IQ applies predictive analytics and automated geospatial modeling to this field-tested foundation. The system synthesizes terrain, hydrologic, engineering and ecological data to assess broad geographic regions simultaneously. By rapidly screening large areas, EcoSite IQ allows RES to focus technical diligence on project sites with the highest ecological and economic value.

Initial applications of the methodology centered on water-resource initiatives, screening for projects capable of delivering verified hydrologic benefits. Early deployments have surfaced individual opportunities with estimated annual water yields between 26 million and 665 million gallons. RES is already expanding EcoSite IQ to evaluate water quality credits, watershed restoration, riparian habitats and terrestrial biodiversity.

“EcoSite IQ increases assessment accuracy, helping our clients make sound capital decisions across their land assets by evaluating project viability faster and with greater precision,” said Roger Wiederkehr, CEO of RES. “By combining historical field data with hydrologic and geospatial models, we provide clients key information to prioritize land and water investments across entire geographies.”

Traditional environmental site evaluation relies heavily on manual desktop reviews and individual parcel checks, which restricts the search radius and slows feasibility assessments. EcoSite IQ automates early data synthesis, expanding the screening footprint while uncovering viable restoration opportunities that conventional methods often overlook.

RES has filed a provisional patent application for the EcoSite IQ methodology and continues to expand the system’s analytical capabilities and underlying datasets.

Contact
Jeff McKito
Sr. Manager, Communications
www.res.us
Ph. 806-241-1591

About RES
RES (www.res.us) is the nation’s largest dedicated provider of Nature-based Solutions (NbS), restoring wetlands, prairies, habitats, streams, floodplains and coastal systems. RES’ integrated team designs, builds and guarantees long-term ecosystem performance, combining local expertise across eco-regions with a proven track record of impactful restoration.

View original content to download multimedia:https://www.prnewswire.com/news-releases/res-launches-ecosite-iq-to-accelerate-environmental-project-identification-302900353.html

SOURCE Resource Environmental Solutions, LLC

LONDON, Oct. 6, 2026 /PRNewswire/ — The “Cell Culture Monitoring Biosensors Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2032” report has been added to the Credence Research Inc. offering.

The global Cell Culture Monitoring Biosensors Market was valued at USD 413.8 million in 2024 and is projected to reach USD 906.56 million by 2032, registering a CAGR of 10.3% during the forecast period. Market growth is supported by rising demand for real-time, non-invasive cell analysis across biologics development, cell therapy, high-throughput research and bioprocess control. Optical, electrochemical and microfluidic biosensors are increasingly integrated with automated culture platforms to improve monitoring accuracy, reduce manual sampling and detect process deviations earlier.

Key Takeaways

The Cell Culture Monitoring Biosensors Market is projected to increase from USD 413.8 million in 2024 to USD 906.56 million by 2032 at a CAGR of 10.3%.Optical biosensors led the technology segment with about 39% share in 2024, supported by strong use in real-time and label-free cell analysis.Cell proliferation and viability monitoring accounted for nearly 42% share, reflecting broad use in drug development, toxicity testing and biopharmaceutical production.Pharmaceutical and biotechnology companies represented roughly 51% of end-user demand in 2024.North America leads with about 38% share, followed by Europe at nearly 29% and Asia Pacific at around 23%.Microfluidic miniaturization, AI-enabled predictive monitoring and high-throughput automation are major technology trends shaping product development.

Scope & Segmentation – Cell Culture Monitoring Biosensors Market

The report provides a comprehensive analysis of the global Cell Culture Monitoring Biosensors Market, covering revenue forecasts through 2032. It evaluates market drivers, technology trends, adoption challenges, growth opportunities, competitive positioning and regional demand across research and biopharmaceutical environments.

The study examines how biosensors are used to track cell proliferation, viability, metabolism and differentiation without disrupting culture conditions. It also assesses the expanding use of optical, electrochemical, mechanical and microfluidic platforms across pharmaceutical and biotechnology companies, academic institutes and contract research or service providers.

The Cell Culture Monitoring Biosensors Market is segmented based on technology, application, end user and geography.

By Technology, the market includes Optical Biosensors, Electrochemical Biosensors, Mechanical Biosensors, Microfluidic Biosensors and Others.By Application, the market includes Cell Proliferation & Viability Monitoring, Cell Metabolism Monitoring, Cell Differentiation Monitoring, Cell-Based Assays and Others.By End User, the market includes Pharmaceutical & Biotechnology Companies, Academia & Research Institutes, CROs & Service Providers and Others.By Geography, the market includes North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Access crucial information at unmatched prices!

Request your sample report today and start making informed decisions powered by Credence Research Inc. https://www.credenceresearch.com/report/cell-culture-monitoring-biosensors-market

Why This Report Matters

The report provides a detailed view of biosensor technologies supporting real-time cell culture analysis, process control and high-throughput research.It helps decision-makers understand how biologics, cell therapy and regenerative medicine pipelines are increasing the need for continuous monitoring.The study evaluates the role of microfluidics, AI analytics and automation in reducing manual sampling, improving consistency and accelerating laboratory workflows.For biopharma companies, CROs, research institutes, technology suppliers and investors, the report provides intelligence to support platform selection, product strategy and market expansion.

Market Overview

• Industry Landscape and Value Chain Assessment
• Supply-Side Evaluation
• Demand-Side Evaluation
• Stakeholder Mapping
• Porter’s Five Forces Review
• PESTLE Environment Assessment
• Market Forecast and Future Direction
• Short-Term Forecast, 0–2 Years
• Mid-Term Forecast, 3–5 Years
• Long-Term Forecast, 5–10 Years
• Market Entry and Expansion Strategy

Market Insights

• Customer and End-User Analysis
• Technology Performance Assessment
• Growth Opportunity Assessment
• Bioprocess and Research Workflow Review
• Pricing and Adoption Cost Analysis
• Regulatory and Quality Control Assessment
• Automation and Data Integration Analysis
• Risk and Integration Challenge Assessment
• Investment Return and Market Expansion Assessment

Key Attributes

Segmentation

By Technology

• Optical Biosensors
• Electrochemical Biosensors
• Mechanical Biosensors
• Microfluidic Biosensors
• Others

By Application

• Cell Proliferation & Viability Monitoring
• Cell Metabolism Monitoring
• Cell Differentiation Monitoring
• Cell-Based Assays
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Academia & Research Institutes
• CROs & Service Providers
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Market Growth Driven by Real-Time Cell Analysis and Expanding Biopharmaceutical Pipelines

Laboratories and bioprocessing facilities are shifting from periodic manual sampling toward continuous biosensor-based monitoring. Real-time measurement of cell health, growth and metabolic status can improve culture consistency, reduce contamination risk and shorten experimental decision cycles.

The expansion of biologics, gene therapies and cell therapies further strengthens demand. Sensitive workflows involving CAR-T cells, stem cells and monoclonal antibody production require tighter control of viability, purity and functional performance, increasing the value of high-frequency monitoring.

Regulatory expectations for process validation and manufacturing consistency also support adoption. Biosensors can provide richer process data and enable earlier intervention when culture conditions move outside expected ranges, improving confidence in development and scale-up workflows.

Automation, Microfluidics and AI Expand Biosensor Capabilities

Automation is increasing the value of cell culture biosensors by linking sensing platforms with robotic workstations, high-throughput screening systems and digital bioprocess environments. Integrated monitoring can reduce manual handling while improving the consistency of repeated assays.

Microfluidic and miniaturized biosensors are creating opportunities for lower-volume analysis, rapid screening and single-cell workflows. These platforms can reduce reagent consumption while enabling high-precision measurements in compact formats suited to research and early-stage process development.

AI-based analytics are adding predictive capabilities by identifying patterns in growth, nutrient levels and metabolic behavior. As laboratories generate larger continuous datasets, machine learning can support anomaly detection and earlier corrective action, creating a path toward more automated culture management.

Market Challenges Include High Platform Costs and Complex System Integration

Advanced optical and microfluidic biosensors can require expensive instruments, specialized consumables and high-performance imaging or sensing components. These costs can restrict adoption among smaller laboratories and academic centers with limited capital budgets.

Recurring consumable expenses also influence the economics of broader deployment. Buyers must weigh the value of continuous monitoring against assay volume, process criticality and the cost of alternative analytical workflows.

Integration with existing bioreactors, microfluidic chips and automated workstations can be technically demanding. Labs may require custom interfaces, validation work and workflow changes before new biosensors can be used consistently across established processes.

Calibration, data compatibility and specialist expertise add further operational complexity. Suppliers that simplify integration and provide strong technical support will be better positioned to expand adoption across regulated and research-driven environments.

Key Player Analysis

• Lifeonics Ltd.
• Sarissa Biomedical Ltd.
• Nova Biomedical
• C-CIT Sensors AG
• Conductive Technologies Inc.
• Cardea
• Roche
• Lonza

Recent Industry Developments

In 2025, Roche announced an investment of up to USD 550 million to expand its diagnostics manufacturing hub in Indianapolis, increasing capacity across its diagnostics operations.In 2023, Lonza introduced TheraPEAK T-VIVO Cell Culture Medium, a chemically defined formulation designed to support and accelerate CAR-T cell manufacturing workflows.

Report Coverage

The research report offers an in-depth analysis based on Technology, Application, End User and Geography. It details leading market players and provides an overview of their businesses, product offerings, investments and key applications.The report includes insights into the competitive environment, SWOT analysis, current technology trends, major market drivers and adoption constraints.The study further assesses bioprocess automation, regulatory requirements, data integration and technological advances influencing the Cell Culture Monitoring Biosensors Market.It provides strategic recommendations for new entrants and established companies seeking to navigate the evolving market for real-time cell culture monitoring technologies.

Access crucial information at unmatched prices!

Request your sample report today and start making informed decisions powered by Credence Research Inc. https://www.credenceresearch.com/report/cell-culture-monitoring-biosensors-market

Shape Your Report to Specific Countries or Regions and Enjoy 30% Off!

Customize Now

Related Reports –

https://www.credenceresearch.com/report/bioprocess-analyzers-market

https://www.credenceresearch.com/report/bioprocess-analysers-market

https://www.credenceresearch.com/report/biopharmaceutical-fermentation-market

https://www.credenceresearch.com/report/bioprocess-validation-market

https://www.credenceresearch.com/report/cell-culture-monitoring-biosensors-market

About Us

Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics.

The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter’s Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm’s client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa.

To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn and Facebook

Contact Us –
Credence Research Inc,
Tower C-1105, S 25,
Akash Tower,
Vishal Nagar,
Pimple Nilakh, Haveli,
Pune – 411027, India
USA: +1-888-600-6441
Email: sales@credenceresearch.com
Visit Our Website: https://www.credenceresearch.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/cell-culture-monitoring-biosensors-market-to-reach-usd-906-56-million-by-2032–credence-research-302900269.html

SOURCE Credence Research Inc.